How Much Does Zepbound Cost in Hawaii in 2026?

Zepbound Retail Pricing in Hawaii

The manufacturer list price set by Eli Lilly for Zepbound is $1,059 per month, and Hawaii retail pharmacies reflect that number almost exactly in 2026. This price applies to all five dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, and 15 mg) as a four-pen, four-week supply [1]. Because Hawaii's pharmacy market is concentrated on Oahu and across a small number of island-based chains, cash-pay pricing shows minimal variation between retailers.

Patients paying out of pocket at CVS, Walgreens, Longs Drugs, or independent pharmacies on any island will encounter prices clustered tightly around that $1,059 figure. Some pharmacies on neighbor islands (Maui, Big Island, Kauai) may add modest markups for logistics, though this remains uncommon with direct wholesale distribution. Prescription discount aggregators like GoodRx or RxSaver occasionally list prices between $1,000 and $1,100 for Zepbound in Honolulu ZIP codes, but savings rarely exceed 5% to 8% off list without insurance or a manufacturer coupon.

For context, the FDA-approved prescribing information for Zepbound covers its use in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia [1]. Hawaii's obesity prevalence sits at approximately 24%, below the national average of 41.9%, yet demand for GLP-1/GIP receptor agonists has grown sharply across all islands since 2024.

Hawaii Medicaid and Zepbound Coverage

Hawaii Medicaid does not cover Zepbound for chronic weight management as of May 2026. This exclusion applies across all Hawaii Medicaid managed care plans, including AlohaCare, HMSA, Kaiser, and UnitedHealthcare Community Plan. The restriction follows a pattern seen in most state Medicaid programs, where anti-obesity medications remain classified as optional benefits rather than mandatory covered drugs [2].

Why the gap? Federal Medicaid law does not require states to cover drugs prescribed solely for weight loss. Hawaii has not opted into the voluntary coverage pathway that a small number of states (fewer than ten as of 2026) have adopted. Patients enrolled in Hawaii Medicaid who have a BMI ≥30 and a co-occurring condition like type 2 diabetes may have a narrow pathway to appeal for coverage under a comorbidity-based exception, but approvals are rare and require extensive clinical documentation.

The Endocrine Society's 2024 clinical practice guideline on pharmacotherapy for obesity recommends tirzepatide as a first-line option for adults with BMI ≥30, calling it "the most effective single-agent pharmacotherapy for obesity currently available" [3]. Despite this recommendation, Medicaid formulary committees in Hawaii have cited budget impact analyses projecting annual per-member costs exceeding $12,000 as the primary barrier to inclusion.

Patients on Hawaii Medicaid seeking weight management support should discuss alternative covered options with their provider, including older agents such as phentermine-topiramate or naltrexone-bupropion, which carry lower efficacy but are formulary-listed in most Hawaii managed care plans.

Commercial Insurance Coverage in Hawaii

Commercial insurers in Hawaii vary significantly in their Zepbound formulary decisions. HMSA, the state's largest private insurer covering roughly 50% of the commercially insured population, added Zepbound to its formulary in late 2025 with prior authorization and step therapy requirements. Kaiser Permanente Hawaii covers tirzepatide for type 2 diabetes (as Mounjaro) but maintains a more restrictive policy for the obesity indication under the Zepbound label.

Prior authorization criteria typically require documented BMI ≥30 (or ≥27 with a comorbidity), a failed trial of lifestyle intervention lasting at least six months, and in some cases, failure of at least one prior anti-obesity medication. Processing times in Hawaii run 5 to 14 business days for standard requests.

For patients with employer-sponsored plans administered by national carriers (Aetna, Cigna, UnitedHealthcare), coverage depends on whether the employer elected the obesity benefit rider. A 2025 survey by the Purchaser Business Group on Health found that 44% of large employers now cover at least one GLP-1 receptor agonist for weight management, up from 26% in 2023 [4].

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "Insurance coverage for anti-obesity medications remains the single biggest barrier to treatment access in the United States. The evidence base for tirzepatide is stronger than for any previous obesity pharmacotherapy, and coverage policies need to reflect that reality" [3].

If your plan covers Zepbound, expect a specialty-tier copay ranging from $50 to $150 per month after meeting your deductible. Plans that do not list Zepbound on formulary will price it at the full $1,059 retail cost.

The Eli Lilly Savings Card in Hawaii

Eli Lilly's Zepbound Savings Card program operates in Hawaii and can reduce out-of-pocket costs to $25 per monthly fill for eligible patients. The card is available to commercially insured patients whose plan covers Zepbound but imposes a copay, and also to patients whose commercial insurance does not cover Zepbound at all (in which case the savings card provides a larger discount, though the patient still pays more than $25).

Key eligibility rules for Hawaii residents:

• Must have commercial (private) insurance. Patients on Medicare, Medicaid, TRICARE, or other federal/state government programs are not eligible.
• Must have a valid prescription from a licensed prescriber.
• The savings card covers up to $563 per monthly fill for commercially insured patients, with the patient responsible for the remainder.
• For patients whose commercial plan does not cover Zepbound, the card may still reduce costs, but the net price will exceed $25 and typically lands between $500 and $600 per month.

Enrollment is handled online through Lilly's official portal or by phone. Hawaii pharmacies process the card as a secondary claim after running the primary insurance. The program does not currently have an annual cap for 2026, though Lilly reserves the right to modify terms [1].

Compounded Tirzepatide in Hawaii

Compounded tirzepatide is available in Hawaii through licensed 503A compounding pharmacies. These pharmacies can legally prepare tirzepatide formulations when a patient holds a valid individual prescription from a licensed provider. The typical cost runs approximately $249 per month, representing a 76% reduction from the brand-name Zepbound price [5].

Hawaii's Board of Pharmacy regulates 503A compounding under state law, aligning with the federal Drug Quality and Security Act (DQSA) framework. A 503A pharmacy must compound in response to a patient-specific prescription and cannot produce large batches for general distribution (that falls under 503B outsourcing facility rules, which carry different FDA oversight requirements).

Several points matter for Hawaii patients considering compounded tirzepatide. First, compounded drugs are not FDA-approved products. They do not undergo the same manufacturing review, bioequivalence testing, or stability studies as branded Zepbound [5]. The FDA's guidance on compounding makes this distinction explicit.

Second, the tirzepatide shortage status affects compounding legality. Under federal law, 503A pharmacies can compound copies of commercially available drugs only when those drugs are on the FDA Drug Shortage List. As of May 2026, tirzepatide's shortage status has fluctuated. Patients should verify current shortage status on the FDA Drug Shortage Database before filling a compounded prescription, because if tirzepatide is removed from the shortage list, compounding a copy becomes legally questionable [5].

Third, not all compounded formulations use the same concentration, injection volume, or excipient profile. Patients switching between compounded tirzepatide and brand Zepbound should work closely with their prescriber to confirm dosing equivalence.

Telehealth Access to Zepbound in Hawaii

Hawaii permits telehealth prescribing of Zepbound, and several national telehealth platforms serve Hawaii residents. This is particularly relevant for patients on neighbor islands where endocrinology and obesity medicine specialists are scarce. Maui County, Hawaii County, and Kauai County each have fewer than five board-certified obesity medicine physicians.

Telehealth platforms operating in Hawaii (including Ro, Hims, Found, and Calibrate) can prescribe Zepbound if the provider holds a valid Hawaii medical license or practices under the Interstate Medical Licensure Compact. Hawaii joined the Compact in 2019, expanding the pool of eligible prescribers.

A typical telehealth visit for Zepbound in Hawaii costs $50 to $199 for the initial consultation, with follow-up visits ranging from $29 to $99. Some platforms bundle the consultation fee into a monthly membership that includes prescription management, lab monitoring, and nutritional guidance. Patients should confirm whether the platform's pharmacy network can ship temperature-controlled medications to Hawaii addresses, as Zepbound requires refrigeration prior to first use (the pen is stable at room temperature for up to 21 days once removed from refrigeration) [1].

The SURMOUNT-1 trial, published in the New England Journal of Medicine, demonstrated that tirzepatide at the 15 mg dose produced 22.5% mean body weight reduction at 72 weeks compared to 2.4% with placebo (N=2,539). The 10 mg dose achieved 21.4% and the 5 mg dose achieved 16.0% [6]. These results established tirzepatide as the most effective single-molecule anti-obesity agent studied in a phase 3 trial to date.

How to Get the Lowest Price on Zepbound in Hawaii

Reducing your Zepbound costs in Hawaii depends on your insurance status. Here is a practical breakdown by scenario.

Commercially insured, plan covers Zepbound: Use the Eli Lilly savings card to reduce your copay to $25 per fill. This is the lowest achievable price for most Hawaii residents with private insurance.

Commercially insured, plan does not cover Zepbound: Apply the Eli Lilly savings card for a partial discount (expect $500 to $600 per month net). Simultaneously, ask your provider to submit a prior authorization appeal. Include documentation of BMI, comorbidities, and failed lifestyle interventions. If denied, file a formal appeal. Hawaii's insurance commissioner requires plans to respond to appeals within 30 calendar days.

Uninsured or self-pay: Consider compounded tirzepatide from a licensed Hawaii 503A pharmacy at roughly $249 per month. Alternatively, check Lilly's LillyDirect program, which has periodically offered Zepbound vials (not pens) at reduced pricing for cash-pay patients in select markets.

Hawaii Medicaid enrollees: Brand Zepbound is not covered. Discuss alternative covered anti-obesity medications with your provider. If you have a comorbidity like type 2 diabetes, ask whether Mounjaro (same molecule, different FDA indication) might be covered under your plan's diabetes formulary.

Dosing, Titration, and What to Expect

Zepbound treatment begins at 2.5 mg once weekly for four weeks. This starting dose is for tolerability, not therapeutic effect. After four weeks, the dose increases to 5 mg weekly. From there, the prescriber may titrate upward in 2.5 mg increments every four weeks based on clinical response and tolerability, up to a maximum of 15 mg weekly [1].

Common side effects reported in SURMOUNT-1 included nausea (24% to 33% across dose groups), diarrhea (18% to 25%), constipation (11% to 17%), and injection-site reactions (3% to 7%) [6]. Nausea is most pronounced during the first four to eight weeks and typically diminishes as the body adjusts. The discontinuation rate due to adverse events was 4.3% to 7.1% across tirzepatide groups versus 2.6% for placebo [6].

Patients in Hawaii should plan for monthly pharmacy visits or mail-order refills. Each prescription covers a four-week supply (four single-dose pens). Lab monitoring, including a basic metabolic panel and lipid profile, is recommended at baseline and every three to six months during treatment per the American Association of Clinical Endocrinology obesity guidelines [7].

Treatment duration data from SURMOUNT-3 and SURMOUNT-4 indicate that weight regain occurs when tirzepatide is discontinued, with participants regaining approximately two-thirds of lost weight within one year of stopping the drug [8]. This positions Zepbound as a long-term (potentially indefinite) therapy for most patients, which makes cost planning especially relevant for Hawaii residents managing ongoing monthly expenses.